Previous Close | 0.2610 |
Open | 0.2610 |
Bid | 0.2420 x 1100 |
Ask | 0.2432 x 1100 |
Day's Range | 0.2371 - 0.2610 |
52 Week Range | 0.2000 - 9.0000 |
Volume | |
Avg. Volume | 2,179,105 |
Market Cap | 3.421M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0570 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.00 |
As the adage goes, “where there’s risk, there’s reward.” Unfortunately, this is not universal when it comes to penny stocks. While there are plenty of stocks in “penny territory” (under $5 per share) that are strong opportunities, there are also scores of low-priced names best characterized as penny stocks to sell. When it comes to risk/reward, names in this category offer a lot of former, but an inadequate amount of latter. For the most part, stocks at this price level are one of two things. Th
Press release Boston, MA U.S.A. (January 20, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care today announced that the Company’s 2023 Annual Meeting of Stockholders (the “Meeting”), on January 19, 2023, at 1:00 p.m. (Eastern Time) was adjourned without any business being conducted. The Meeting was adjourned until Frid
PRESS RELEASE Boston, MA U.S.A. (December 1, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced that the Company’s adjourned 2022 Annual Stockholders Meeting (“2022 ASM”) set for December 2, 2022 has been cancelled and a new meeting date for the Annual Stockholders Meeting (“2023 ASM”) will be held, as